上海医药注射用头孢唑林钠通过仿制药一致性评价

Core Viewpoint - Shanghai Pharmaceuticals (601607) announced that its subsidiary, Shanghai Shenyang New Asia Pharmaceutical Co., Ltd., received the approval notice from the National Medical Products Administration for the injectable Cefazolin Sodium, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The injectable Cefazolin Sodium is indicated for the treatment of infections caused by sensitive bacteria, including respiratory infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, sepsis, infective endocarditis, liver and biliary system infections, reproductive system infections, and for the prevention of perioperative infections [1]